Dishman Carbogen Amcis' record carries seven consecutive unqualified audit opinions, but the profit those opinions certify is shaped by a goodwill amortisation life stretched to 99 years, and the balance sheet is under strain from covenant breaches and related-party funding. The standalone entity loses money while profit sits in subsidiaries, and the promoter family controls both the board and the key financing routes.
Key findings
- Unqualified opinions sit alongside recurring audit trail gaps and a subsidiary going-concern uncertainty
Major- T R Chadha & Co. LLP issued unqualified opinions for every year from FY2019-20 through FY2025-26. However, the audit trail feature was not enabled at the database level for the HANA database in FY2023-24, FY2024-25, and FY2025-26. The auditor also raised a material uncertainty on the going concern of subsidiary Carbogen AMCIS Holding AG in FY2023-24 after its loans became callable on demand. - Consolidated profit is concentrated in subsidiaries, 17-20 of which the principal auditor did not audit
Major- Consolidated PAT was ₹16.16 crore versus a standalone loss of ₹-64.98 crore in the latest year. In FY2025-26, 17 subsidiaries were not audited by the principal auditor, reflecting total assets of ₹18,292.06 crore and revenues of ₹3,606.70 crore. The subsidiary count fell from 22 in FY2021 to 17 in FY2026 through mergers and strike-offs. - Promoter family draws pay through multiple channels, including a Swiss subsidiary salary
Major- Global MD Mr. Arpit J. Vyas drew no remuneration from the company in FY2025-26 but received CHF 8,54,608 from Swiss subsidiary CARBOGEN AMCIS AG. Chairman Mr. Janmejay R. Vyas received up to ₹1.1 crore annually for professional services under a ₹2 crore per annum approval. The company paid commission to Independent Directors in FY2022-23 through FY2025-26 despite losses in each year. - Joint auditors replaced by a single firm at half the fee, then raised back
Minor- The two joint auditors, serving since FY2015-16, were replaced by T R Chadha & Co. LLP at the 20 July 2021 AGM at ₹30 lakh per annum, versus the prior aggregate fee of ₹62 lakh. Fees paid to the new auditor and network entities rose to ₹55 lakh by FY2025-26. The Board recommended reappointment for a second five-year term at ₹55 lakh per annum on 19 May 2026. - Bavla CEPs suspended for four years, while tax search and exchange fines were minor
Minor- The Swissmedic/EDQM inspection of Bavla in March 2020 suspended Certificates of Suitability and depressed production until GMP certificates were received in early 2024. The 19 December 2019 income-tax search produced no demand as of the FY2019-20 report date. Exchange penalties were trivial: ₹5,900 and ₹11,800 for late and incorrect filings.
What to watch
- NCD repayment. ₹35.38 crore principal on ISIN INE385W07034 is due 15 July 2026.
- Covenant waivers. Balance waivers for the ₹84.44 crore Debenture Series 2024 and 2025 deviation remained awaited as of the FY2025-26 approval date.
- ECB infusion. Funds from Aamanya AG were expected within 60-90 days from the June 2026 Q1 FY27 transcript.
- Promoter pledge. Any pledge of listed shares to secure the ECB "could be for a brief period or for a smaller amount" as of June 2026.
- Goodwill impairment test. The FY2026-27 annual test outcome will be disclosed in the FY2026-27 Annual Report.
Bottom line: This is an audited record with a clean opinion every year, but the opinion rests on a goodwill life the Board itself extended to 99 years, and the cash to run India operations is coming from the promoter's personal borrowing. The risk is concentrated in two places: the sustainability of reported profit and the refinancing of India debt. Watch the waiver receipts and the ECB arrival, and read the goodwill note before the profit line.